Jack Kenney
Investing Profile
SV Health Investors thesis
Rondo Therapeutics is a biopharmaceutical company breaking new ground in cancer therapy. The company’s mission is to advance bispecific antibody therapies that address unmet needs in the treatment of solid tumors. Rondo is developing a new class of bispecific antibodies designed to harness the immune system to target and eliminate tumors with enhanced safety. Rondo Therapeutics is supported by Canaan Partners, Red Tree Venture Capital, Johnson & Johnson, SV Health Investors, and Novo Holdings. In addition to RNDO-564, the company’s pipeline includes immune-engaging bispecifics for a range of s
Sector and stage focus
- Series B: BioTech
- Seed: BioTech
- general: Investors who invested in female founders, Israel, Investors who invested in diverse founders, Boston / New England
- Series A: BioTech
- Pre-seed: BioTech
Recent investments by Jack Kenney
Jack Kenney has 5 named past investments in the public record. The most recent:
| Company | Stage | Date | Round size |
|---|---|---|---|
| Caraway Therapeutics | Series A | Nov 2018 | $23M |
| Xilio Therapeutics | Series B | Mar 2020 | $100M |
| Catamaran Bio | Seed | Jan 2020 | $4.5M |
| Pionyr Immunotherapeutics | Series A | Jan 2017 | $8.5M |
| Cellinta | Seed | Feb 2020 | $5M |
Frequent co-investors
Jack Kenney has co-invested with: Carol Gallagher.
Is Jack Kenney a fit for your round?
Upload your pitch deck and see whether Jack Kenney appears in your top 20 matches.
Find investors for your deck